Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.

Vitanza NA, Monje M.

Curr Treat Options Neurol. 2019 Jul 10;21(8):37. doi: 10.1007/s11940-019-0577-y. Review.

PMID:
31290035
2.

Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.

Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA.

Acta Neuropathol Commun. 2018 Nov 5;6(1):117. doi: 10.1186/s40478-018-0614-1.

3.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
4.

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL.

Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.

5.

Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.

Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA.

Acta Neuropathol. 2015 Dec;130(6):815-27. doi: 10.1007/s00401-015-1478-0. Epub 2015 Sep 23.

6.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP.

J Neurooncol. 2019 Aug 27. doi: 10.1007/s11060-019-03271-3. [Epub ahead of print]

PMID:
31456142
7.

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.

Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C.

Acta Neuropathol. 2012 Sep;124(3):439-47. doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3.

8.

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM.

Oncotarget. 2018 Dec 14;9(98):37112-37124. doi: 10.18632/oncotarget.26430. eCollection 2018 Dec 14. Erratum in: Oncotarget. 2019 Apr 12;10(28):2788.

9.

H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.

Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ.

Acta Neuropathol. 2019 Apr;137(4):637-655. doi: 10.1007/s00401-019-01975-4. Epub 2019 Feb 15. Erratum in: Acta Neuropathol. 2019 Jun;137(6):1021.

PMID:
30770999
10.

Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.

Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Santi M, Cruz CR, Packer RJ, Almira-Suarez MI, Hwang EI, Nazarian J.

J Neuropathol Exp Neurol. 2019 May 1;78(5):380-388. doi: 10.1093/jnen/nlz021.

11.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

12.

Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

Gwak HS, Park HJ.

Crit Rev Oncol Hematol. 2017 Dec;120:111-119. doi: 10.1016/j.critrevonc.2017.10.013. Epub 2017 Oct 31. Review.

PMID:
29198324
13.

Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.

Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A.

Brain Pathol. 2016 Sep;26(5):569-80. doi: 10.1111/bpa.12336. Epub 2015 Dec 14.

14.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

15.

Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.

Zhang R, Han J, Daniels D, Huang H, Zhang Z.

J Neurooncol. 2016 Jan;126(1):27-36. doi: 10.1007/s11060-015-1936-5. Epub 2015 Sep 16.

16.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

17.

Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.

Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C.

Acta Neuropathol. 2014 Oct;128(4):573-81. doi: 10.1007/s00401-014-1319-6. Epub 2014 Jul 22.

18.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
19.

Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology.

Schroeder KM, Hoeman CM, Becher OJ.

Pediatr Res. 2014 Jan;75(1-2):205-9. doi: 10.1038/pr.2013.194. Epub 2013 Nov 5. Review.

PMID:
24192697
20.

Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.

Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, Cha S.

AJNR Am J Neuroradiol. 2017 Apr;38(4):795-800. doi: 10.3174/ajnr.A5076. Epub 2017 Feb 9.

Supplemental Content

Support Center